The development of drotrecogin alfa (activated) for the treatment of severe sepsis.
Macias
W L
WL
Lilly Laboratory for Clinical Research, Eli Lilly and Company, Indianapolis, Indiana 46285, USA. Macias_William_L@Lilly.com
Yan
S B
SB
Grinnell
B W
BW
D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects* / Q000276:immunology; D011486:Protein C / Q000276:immunology* / Q000494:pharmacology / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D018805:Sepsis / Q000188:drug therapy*
D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated